MARKET

INCY

INCY

Incyte Corp
NASDAQ
69.05
+2.72
+4.10%
After Hours: 69.05 0 0.00% 16:24 02/12 EST
OPEN
66.30
PREV CLOSE
66.33
HIGH
69.10
LOW
65.56
VOLUME
2.08M
TURNOVER
--
52 WEEK HIGH
83.95
52 WEEK LOW
50.35
MARKET CAP
13.36B
P/E (TTM)
445.77
1D
5D
1M
3M
1Y
5Y
1D
Incyte Corp. Stock Climbs 4.1%, Outperforms Competitors
Dow Jones · 6h ago
Reevaluating Incyte Corporation After Earnings (Technical Analysis)
Seeking Alpha · 14h ago
Incyte’s Earnings Call: Robust Growth Amid Challenges
TipRanks · 1d ago
Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade
Seeking Alpha · 1d ago
JMP Securities Reiterates Market Perform on Incyteto Market Perform
Benzinga · 1d ago
Incyte Is Maintained at Sector Perform by RBC Capital
Dow Jones · 1d ago
Incyte Price Target Cut to $68.00/Share From $70.00 by RBC Capital
Dow Jones · 1d ago
RBC Capital Maintains Sector Perform on Incyte, Lowers Price Target to $68
Benzinga · 1d ago
More
About INCY
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonists targeting Mas-related G protein-coupled receptor X2 (MRGPRX2) for the treatment of various mast cell mediated disorders and MRGPRX4 for cholestatic pruritus.

Webull offers Incyte Corp stock information, including NASDAQ: INCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INCY stock methods without spending real money on the virtual paper trading platform.